復星醫藥(600196.SH):Gland Pharma向印度的公司註冊處遞交非正式招股書
格隆匯 11 月 3日丨復星醫藥(600196.SH)披露分拆Gland Pharma境外上市進展,公司獲通知,於2020年10月31日,Gland Pharma向印度的公司註冊處(位於印度特倫甘地的海德拉巴,“公司註冊處”)遞交日期為2020年10月31日的非正式招股書(即“RHP”,RHP並未包括GlandPharma每股股份發行價格及募資規模之詳情,下同)。電子形式遞交的RHP已在公司註冊處注冊,且RHP已於2020年11月2日遞交SEBI、孟買證交所及印度證交所。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.